ELCC 2016

Patients With EGFR-expressing NSCLC Benefit From Addition of Necitumumab

Patients With EGFR-expressing NSCLC Benefit From Addition of Necitumumab

By

Subgroup of patients with EGFR mutation-positive non-small cell lung cancer (NSCLC) benefitted from the addition of necitumumab to gemcitabine plus cisplatin.

Immunotherapy With Live Bacterium Plus Chemo Improves Response Rate in Pleural Mesothelioma

Immunotherapy With Live Bacterium Plus Chemo Improves Response Rate in Pleural Mesothelioma

By

CRS-207 plus chemotherapy demonstrated encouraging clinical activity in patients with malignant pleural mesothelioma.

Osimertinib Efficacious as First-line Treatment of EGFR-mutant NSCLC

Osimertinib Efficacious as First-line Treatment of EGFR-mutant NSCLC

By

Osimertinib is efficacious for the first-line treatment of patients with EGFR mutation-positive non-small cell lung cancer (NSCLC).

Study Underscores Role of Osimertinib in EGFR-TKI-pretreated NSCLC

Study Underscores Role of Osimertinib in EGFR-TKI-pretreated NSCLC

By

Updated data from a phase 1 cohort and a pooled analysis of 2 phase 2 trials demonstrated that osimertinib therapy resulted in a high overall response rate.

Durvalumab Plus Gefitinib Active in EGFR-mutant NSCLC

Durvalumab Plus Gefitinib Active in EGFR-mutant NSCLC

By

Durvalumab plus demonstrated encouraging activity with favorable tolerability in non-small cell lung cancer (NSCLC).

Type of Chemo in CRT Regimen Does Not Impact Brain Metastases Development

Type of Chemo in CRT Regimen Does Not Impact Brain Metastases Development

By

Type of chemotherapy regimen for the treatment of patients with stage 3 non-small cell lung cancer (NSCLC) does not influence who will develop brain metastases.

Despite Encouraging Activity of Osimertinib + Durvalumab, Safety Profile Warrants Further Investigation

Despite Encouraging Activity of Osimertinib + Durvalumab, Safety Profile Warrants Further Investigation

By

Osimertinib in combination with durvalumab demonstrated encouraging clinical activity, but the combination was associated with high rates of toxicities.

Baseline Serum Cytokines May Be Associated With Nivolumab OS Benefit

Baseline Serum Cytokines May Be Associated With Nivolumab OS Benefit

By

Select serum cytokines may be associated with survival benefit in patients with advanced refractory squamous non-small cell lung cancer (NSCLC).

Adding Bevacizumab to Maintenance Pemetrexed Improves PFS in Advanced Nonsquamous NSCLC

Adding Bevacizumab to Maintenance Pemetrexed Improves PFS in Advanced Nonsquamous NSCLC

By

Maintenance therapy with bevacizumab plus pemetrexed improved progression-free survival compared with pemetrexed alone.

Nab-paclitaxel Plus Carboplatin Effective in Older Patients With Squamous Cell Carcinoma

Nab-paclitaxel Plus Carboplatin Effective in Older Patients With Squamous Cell Carcinoma

By

Treatment with nab-paclitaxel plus carboplatin resulted in significant improvement in objective response rate and overall survival.

Ceritinib Displays Whole Body, Intracranial Efficacy in Crizotinib-treated Patients

Ceritinib Displays Whole Body, Intracranial Efficacy in Crizotinib-treated Patients

By

Ceritinib treatment demonstrated clinically meaningful whole body and intracranial activity with an acceptable tolerability profile.

Brigatinib Shows Antitumor Activity in ALK+ NSCLC

Brigatinib Shows Antitumor Activity in ALK+ NSCLC

By

Brigatinib demonstrated antitumor activity in crizotinib-treated and crizotinib-naïve patients with non-small cell lung cancer (NSCLC).

Adding Gefitinib to Pemetrexed, Carboplatin Improves PFS in Lung Adenocarcinoma

Adding Gefitinib to Pemetrexed, Carboplatin Improves PFS in Lung Adenocarcinoma

By

The addition of gefitinib to first-line pemetrexed plus carboplatin prolongs progression-free survival compared with chemotherapy alone and gefitinib alone.

Tolerability-guided Dose Adjustment of Afatinib Reduces Adverse Events

Tolerability-guided Dose Adjustment of Afatinib Reduces Adverse Events

By

Tolerability-guided dose adjustment of the kinase inhibitor afatinib reduced treatment-related adverse events without negatively impacting efficacy.

Third-generation EGFR TKI Active in T790M-positive NSCLC

Third-generation EGFR TKI Active in T790M-positive NSCLC

By

BI 1482694 demonstrated meaningful clinical activity in patients with EGFR TKI-resistant non-small cell lung cancer (NSCLC).

Overtreatment Possible for Clinically Diagnosed Early-stage Lung Cancer

Overtreatment Possible for Clinically Diagnosed Early-stage Lung Cancer

By

Patients with clinically diagnosed early-stage lung cancer were found to have improved cancer-specific survival.

Study Assesses Associations Between EGFR Mutation Subtypes, Patient Characteristics

Study Assesses Associations Between EGFR Mutation Subtypes, Patient Characteristics

By

Different EGFR mutation subtypes are associated with different clinical and demographic characteristics.

First-line Afatinib Improves PFS vs Gefitinib in Advanced NSCLC

First-line Afatinib Improves PFS vs Gefitinib in Advanced NSCLC

By

Afatinib significantly prolonged progression-free survival (PFS) for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC).

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs